Polyrizon

Polyrizon Operating Cash Flow

The Operating Cash Flow of Polyrizon (PLRZ) as of Nov 20, 2026 is -4.53 M USD. In the previous year, Operating Cash Flow was -1.15 M USD — a change of 294.77% (lower).

Operating Cash Flow

-4.53 MUSD

YoY

294.77%

Last updated:

Operating Cash Flow of Polyrizon is 2025 -4.53 M USD. Operating Cash Flow of Polyrizon was 2024 -1.15 M USD. It decreases by 294.77% lower compared to the previous year.

The Polyrizon Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2020
-73,000.00 USD
Jan 1, 2021
-492,000.00 USD
Jan 1, 2022
-1.13 M USD
Jan 1, 2023
-537,000.00 USD
Jan 1, 2024
-1.15 M USD
Jan 1, 2025
-4.53 M USD
The Polyrizon Operating Cash Flow history
YEAROperating Cash FlowYoY
-4.53 MUSD+294.77%
-1.15 MUSD+113.59%
-537,000.00USD-52.56%
-1.13 MUSD+130.08%
-492,000.00USD+573.97%
-73,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polyrizon Stock analysis

What does Polyrizon do? Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements. Polyrizon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polyrizon stock

Operating Cash Flow of Polyrizon is -4.53 M USD in 2025.

Operating Cash Flow of Polyrizon changed from -1.15 M USD to -4.53 M USD, representing a 294.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Polyrizon since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Polyrizon historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Polyrizon

All Key Metrics — Polyrizon